Ligand Appoints Martine Zimmermann to its Board of Directors
The Californer/10255468

SAN DIEGO ~ Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has appointed Martine Zimmermann, PharmD, to its Board of Directors as an independent director. Dr. Zimmermann brings 25 years of global experience in the pharmaceutical industry to Ligand's board.

John W. Kozarich, Ph.D., Chairman of Ligand, commented on the appointment: "We are very pleased to welcome Martine to our board of directors. She brings considerable expertise in development and regulatory affairs at a global level, having held senior roles in which she provided strategic regulatory direction on all phases of drug development and across multiple therapeutic areas. This skillset will be invaluable as we build our portfolio of partnered programs."

Dr. Zimmermann has extensive expertise in regulatory affairs at both small and large pharmaceutical organizations, having worked in the United States, Europe and Asia-Pacific. Throughout her career she has been involved in all phases of drug development and in several therapeutic areas, interacting with relevant regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

More on The Californer

• Marissa Goodbody's The Sloth, the Shrew, & the Cockatoo Takes Young Readers on a Rhyming Adventure
• NEW: Report shows major progress in California on preparing for wildfire, avoiding millions of tons of carbon pollution and toxic smoke
• Governor Newsom on the California Supreme Court ruling Sheriff Bianco illegally seized ballots
• Jacqui Condon Selected to Workers' Compensation Panels for Three Professional Athlete Associations
• Southland Symphony Season Opener - "An American Journey"

Currently, Dr. Zimmermann is the Senior Vice President, Head of Regulatory Affairs and R&D Quality at Ipsen Biopharmaceuticals, a global biopharmaceutical company. Prior to Ipsen, she spent 13 years at Alexion Pharma International where she held several positions including Senior Vice President and Head of Global Regulatory Affairs. She is an active member of several life-sciences trade associations and was a member of the Board of Directors of Caelum Biosciences from 2019 until its acquisition by AstraZeneca in 2021; she has also been a board member of France-based Inventiva (Euronext Paris and Nasdaq: IVA) since 2021. Dr. Zimmermann received her Doctorate in Pharmacy (PharmD) with a specialty in immunology from the Louis Pasteur University, Strasbourg in France.

Ligand Pharmaceuticals Incorporated recently announced that it had appointed Martine Zimmermann, PharmD., to its Board of Directors as an independent director bringing 25 years worth of experience from the pharmaceutical industry with her to Ligand's board according to John W Kozarich Phd., Chairman for Ligand Pharmaceuticals Incorporated who commented "We are very pleased to welcome Martine to our board of directors" adding that "She brings considerable expertise in development and regulatory affairs at a global level"

More on The Californer

• Buddy Reed & The Rip It Ups Bring Their Authentic Blues To Bayside Grange For A Harvest Moon Dan
• Pervaziv AI Adds Collections, Chat Forks and Governed Workflows, Advancing Cortex from Chat to Verified Work
• New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
• Sonoma County's Largest Pop-up Used Book Sale Benefits Five Sonoma County Libraries
• Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)

Dr Zimmermann has extensive experience working with relevant regulatory authorities such as The US Food & Drug Administration (FDA), The European Medicines Agency (EMA) & The Japanese Pharmaceuticals & Medical Devices Agency (PMDA). She is currently Senior Vice President & Head Of Regulatory Affairs & R&D Quality for Ipsen Biopharmaceuticals & was previously Senior Vice President & Head Of Global Regulatory Affairs for Alexion Pharma International for 13 years prior to joining Ipsen Biopharmaceuticals

Dr Zimmermann is also an active member for several life sciences trade associations & was part Of The Board Of Directors For Caelum Biosciences until it was acquired by AstraZeneca In 2021; She has also been part Of The Board Of Directors For France based Inventiva since 2021

Dr Zimmerman holds a Doctorate In Pharmacy With A Specialty In Immunology From Louis Pasteur University Strasbourg In France

---

Show All News | Disclaimer | Report Violation